General Information

Materials from the Centers for Disease Control and Prevention:

• Basic Information on PrEP
• Take Charge:  Talk to Your Doctor About PrEP
• Preexposure Prophylaxis for the Prevention of HIV in the United States: A Clinical Practice Guideline
• Preexposure Prophylaxis for the Prevention of HIV in the United States: Clinical Providers’ Supplement
• Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults
• Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men
• Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users
• CDC’s Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention
• Pre-Exposure Prophylaxis (PrEP) for HIV Prevention, Planning for Potential Implementation in the U.S.

Materials from the U.S. Food and Drug Administration:

• Truvada for PrEP Factsheet — Ensuring Safe and Proper Use
• Truvada for PrEP Safety Information

Other Sites Providing PrEP Resources:

• AIDS Action Committee
• AIDSmap
• AVAC
• Avert
• The Fenway Institute
• Massachusetts Department of Public Health
• My PrEP Experience
• PrEP Watch
• Project Inform
• San Francisco AIDS Foundation (PrEPFacts project)
• Test Positive Aware Network

Selected Recent Articles About PrEP

Please Note:  Research on PrEP is advancing rapidly, and many articles are being published each year.  This section focuses heavily on recent news about PrEP in the past 1 to 2 years.  For additional articles, especially older materials, please search the HIVandhepatitis, TheBody, Poz, and Beta Blog sites under the terms “PrEP” or “pre-exposure prophylaxis.”

• PrEP deemed cost-effective in the Netherlands.  (October 2016, Healio)
• First Statewide PrEP and PEP Education Bill Signed Into Law.  (September 2016, Poz)
• Hey healthcare providers of young gay/queer men: Are you telling them about PrEP?  (September 2016, Beta Blog)
• Is Bone Density Loss on PrEP Higher Than Previously Believed?  (September 2016, Poz)
• Assessing Benefits of Pre-Exposure Prophylaxis Relative to Risks of Drug Resistance.  (September 2016, TheBodyPro)
• Dutch model finds PrEP for high-risk gay men is cost-effective at current prices and cost-saving at generic prices.  (September 2016, AIDSmap)
• New York clinic outlines how to improve uptake of PrEP by transgender people.  (September 2016, AIDSmap)
• PrEP Use May Stunt Bone Growth in Young Men.  (September 2016, Poz)
• PrEP, test-and-treat offer most cost-effective methods for HIV prevention.  (September 2016, Healio)
• Racial Disparities Seen in PrEP Use Among Young Gay and Bi Men in California.  (September 2016, Poz)
• Evidence that “on-demand” PrEP taken before and after sex can prevent HIV.  (September 2016, Beta Blog)
• London gay men anticipate some pros and cons of different PrEP methods – but optimal efficacy is key to acceptability.  (September 2016, AIDSmap)
• Two Women, Both with Stories Showing How Hard It Is for Women to Get PrEP.  (September 2016, AVAC)
• Does PrEP Use Lead to Higher STI Rates Among Gay and Bi Men?  (September 2016, Poz)
• Planned Parenthood in Massachusetts Now Offers Truvada as PrEP.  (September 2016, Poz)
• Study looks at use of PrEP during pregnancy and breastfeeding.  (September 2016, AIDSmap)
• Can We Finally Say That “On-Demand” PrEP Really Does Work?  (August 2016, Poz)
• U.S. PrEP study achieves high levels of engagement and adherence among black men who have sex with men.  (August 2016, AIDSmap)
• Increasing adherence, tailoring interventions may reduce disparities in PrEP uptake.  (August 2016, Healio)
• Making PrEP More Integrated and Available for Primary Care Providers to Prescribe in the U.S. Southeast.  (August 2016, TheBodyPro)
• PrEP and PEP Education Bill Awaits Governor’s Signature.  (August 2016, Poz)
• PrEP Gets the Green Light in Europe.  (August 2016, Poz)
• Women at Risk for HIV Are Often Willing to Take PrEP for Pregnancy.  (August 2016, Poz)
• No new HIV infections seen in San Francisco’s Strut PrEP programme.  (August 2016, AIDSmap)
• Oral Maraviroc PrEP Protects U.S. Women From HIV in 48-Week Study.  (August 2016, TheBodyPro)
• U.K. Court rules PrEP funding within NHS England’s legal jurisdiction.  (August 2016, Healio)
• Vaginal bacteria increase HIV susceptibility and may reduce PrEP effectiveness.  (August 2016, AIDSmap)
• Zero HIV Transmissions in Major San Francisco PrEP Program.  (August 2016, Poz)
• PrEP rollout recipients in France top 1000: full trial results report 97% effectiveness.  (July 2016, AIDSmap)
• What Determines Higher PrEP Adherence Among Black Gay and Bi Men?  (July 2016, Poz)
• High Court rules NHS England is responsible for funding PrEP.  (August 2016, AIDSmap)
• Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most.  (July 2016, AIDSmap)
• Nanoparticles containing dolutegravir demonstrate efficacy for PrEP delivery.  (July 2016, Healio)
• Australia adopts ambitious plan to use PrEP to ‘virtually eliminate’ HIV by 2020.  (July 2016, AIDSmap)
• What we’re learning about new PrEP drugs and delivery methods at AIDS 2016.  (July 2016, Beta Blog)
• No Condoms, No Problems in PrEP Study.  (July 2016, Healio)
• No More Lip Service: A Demand for PrEP Access from the Transgender Community.  (July 2016, Global Forum on MSM and HIV)
• PrEP can further reduce the risk of HIV infection after a partner starts treatment.  (July 2016, AIDSmap)
• Young Gay Teens Do Well On PrEP — But They Need More Support.  (July 2016, Beta Blog); related coverage from MedPage Today
• PrEP use exceeds 79,000 in U.S. pharmacy survey, but some groups lagging behind.  (July 2016, AIDSmap); related coverage from Beta Blog and Poz
• Gay Men at AIDS 2016 Talk PrEP, Chem Sex and Drug Smuggling.  (July 2016, TheBodyPro)
• How do you talk about PrEP to young Black men at risk for HIV?  (July 2016, Beta Blog)
• PrEP can cut new HIV infections by one-third in next decade.  (July 2016, Healio)
• PrEP researchers now focusing on the best ways to get PrEP to people who need it.  (July 2016, AIDSmap)
• With 20 Billion Condoms and 3 Million People on PrEP, Could We Reach the UNAIDS HIV Prevention Goal in 5 Years?  (July 2016, Beta Blog)
• Experts call for England’s National Health Service to fund PrEP.  (July 2016, Healio)
• HIV seroconversion is rare if Truvada PrEP is used consistently.  (July 2016, AIDSmap)
• Keeping Gay Men in Care Is a Major Concern for Long-Term PrEP Use.  (July 2016, Poz)
• Two Women, Both with Stories Showing How Hard It Is for Women to Get PrEP.  (July 2016, Beta Blog)
• Domestic Violence Is Connected to Lower PrEP Adherence Among Women.  (June 2016, Poz)
• Five Exciting HIV Prevention Studies We’re Paying Attention to.  (June 2016, Beta Blog)
• Major PrEP Studies Underline Importance of Adherence.  (June 2016, Poz)
• PrEP Is Popular in San Francisco, but Largely Among White, Older Gay Men.  (June 2016, Poz)
• Sex At Sex Parties, PrEP Takes HIV Disclosure Off the Table.  (June 2016, Beta Blog)
• AMA calls for increased HIV prevention, PrEP education.  (June 2016, Healio)
• PrEP use is rising fast in US, but large racial disparities remain.  (June 2016, AIDSmap); related coverage from Healio and Poz
• Women in HIV serodiscordant relationships less likely to take PrEP consistently if they experience intimate partner violence.  (June 2016, AIDSmap)
• Despite low uptake, more than half of MSM willing to take PrEP.  (June 2016, Healio)
• Introducing PrEP Facts: Women’s Sexuality and HIV Prevention.  (June 2016, AVAC)
• Once Again, England Refuses to Make PrEP Widely Available.  (June 2016, Poz)
• People who inject drugs have other priorities ahead of PrEP.  (June 2016, AIDSmap); related coverage from Poz
• Physicians Are Increasingly Aware of and Willing to Prescribe PrEP.  (June 2016, Poz)
• PrEP not cost-effective for people who inject drugs.  (June 2016, Healio)
• PrEP-Linked Symptoms Peak in First Month, With Modest Adherence Impact.  (June 2016, TheBodyPro)
• STDs Among Gay Men in a New Era of PrEP.  (June 2016, Beta Blog)
• Truvada Whores and HIV Prevention: The Queer Communication of PrEP.  (June 2016, Poz)
• Cost is biggest barrier to PrEP in Europe, ECDC declares.  (June 2016, AIDSmap)
• San Francisco PrEP Program Serves Over 1,000 Clients.  (June 2016, Beta Blog)
• PrEP uptake poised to grow as physicians gain insight, stigmas fade.  (May 2016, Infectious Disease News)
• New resource: Paying for PrEP.  (May 2016, Beta Blog)
• Not If, But When: Gay men gather in Jo-burg to plot PrEP access.  (May 2016, AVAC)
• Project Inform and Outshine NW launch new PrEP awareness videos for transgender community.  (May 2016, Project Inform)
• It’s a Bird! It’s a Plane! It’s the PrEP Superheroes!  (May 2016, Poz)
• Overview of Major PrEP Research Underlines Truvada’s Power to Prevent HIV.  (May 2016, Poz)
• Transmitted drug resistance: The other side to the PrEP failure case we’re not talking about.  (May 2016, Beta Blog)
• Which men stand to benefit most from access to PrEP? (May 2016, AIDSmap)
• 3 New Studies to Provide and Evaluate PrEP Among Trans People. (April 2016, Poz)
• Recent meth use may indicate need for PrEP, study finds.  (April 2016, Beta Blog)
• How Can We Help Young People Under Age 18 Get PrEP?  (April 2016, Beta Blog)
• Legal threat causes NHS England to rethink PrEP access to prevent HIV (April 2016, HIV i-base); related coverage from Poz
• Targeting Injection Drug Users with PrEP Is Not the Best Use of Funds.  (April 2016, Poz)
• People who use drugs still adherent to PrEP.  (April 2016, Beta Blog)
• Introducing Implementation and Access Resources on PrEP Watch.  (April 2016, AVAC)
• Studies Begin to Test Long-Acting Antibody Infusions for HIV Prevention.  (April 2016, Poz); related coverage from NIAID
• Advances reported in long-acting PrEP.  (April 2016, Project Inform)
• PrEP, delivered to your door.  (April 2016, Beta Blog)
• Serious kidney problems are rare with PrEP, but increase with older age and better adherence.  (April 2016, Project Inform)
• Men Are Not Macaques and Other Lessons from Long-Acting PrEP Study.  (March 2016, TheBodyPro)
• From the Front Lines: Gay Men’s Knowledge of New Prevention Strategies.  (Spring 2016, CATIE)
• The Resonance Project: What Service Providers Are Saying About Biomedical Information on HIV Prevention.  (Spring 2016, CATIE)
• Women Need to Adhere Better to PrEP Than Men to Be Protected Against HIV.  (March 2016, Poz)
• England’s PrEP policy in disarray after NHS U-turn.  (March 2016, AIDSmap); related coverage from AVAC and Poz
• Injectable Long-Acting Isentress as PrEP Protects Mice Against Vaginal HIV Exposure.  (March 2016, Poz)
• New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP.  (March 2016, HIV Treatment Bulletin)
• Tailored programmes encourage black gay men to start and stay on PrEP in US study.  (March 2016, AIDSmap); related coverage from
  Project Inform
• PrEP’s Arrival in San Francisco Coincided with Accelerated Increase in Sexual RiskTaking in Gay and Bi Men. (March 2016, Poz)
• High sexually transmitted infection rates among men on PrEP supports more frequent monitoring.  (March 2016, AIDSmap)
• Rapid rise in PrEP awareness in US gay men, but only 5% have used PrEP (AIDSmap)
• Meet the Man Who Got HIV While on Daily PrEP. (March 2016, Poz)
• Canada and Israel OK Truvada as PrEP to Prevent HIV. (March 2016, Poz)
• As many as 185,000 new HIV infections in the U.S. could be prevented by expanding testing, treatment, PrEP. (February 2016, CDC); related coverage from AIDSmap, Poz, Healio, and TheBody
• Almost-certain case of PrEP failure due to drug resistance reported at Retrovirus Conference conference.  (February 2016, AIDSmap); related coverage from Beta Blog, Poz, Project Inform, and TheBody
• CDC guidelines on STI testing for PrEP patients may miss cases.  (February 2016, Healio); related coverage from Poz and 2016 Retrovirus Conference
• Condom use in French PrEP trial: half only used PrEP, a quarter used condoms and PrEP, one in six used neither.  (February 2016, AIDSmap)
• Injectable long-acting cabotegravir shows promise as PrEP in early safety trial.  (February 2016, Poz); related coverage from AIDSmap and abstract from 2016 Retrovirus Conference
• Maraviroc-containing regimens safe, tolerable when taken for HIV prevention (February 2016, National Institute of Allergy and Infectious Diseases – NIAID); related coverage from Poz
• NIH-funded study finds critical population adheres to PrEP with coordinated care.  (February 2016, NIAID)
• NIH-funded study finds effect of PrEP on bone density is reversible.  (February 2016, NIAID); related coverage from AIDSmap, Beta Blog, and Healio)
• PrEP uptake and use by Black men who have sex with men in 3 U.S. cities.  (February 2016, Retrovirus Conference)
• Tailored counseling approach increases PrEP intake among Black MSM  (February 2016, Healio)
• Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low.  (February 2016, AIDSmap)
• Truvada as PrEP against HIV leads to modest decline in kidney function (Poz); related coverage from AIDSmap, Beta Blog, and in CROI abstract 1 and abstract 2
• What is a drug “tail,” and what does it have to do with long-acting PrEP?  (February 2016, Beta Blog)
• What’s on the horizon? New PrEP options presented at Retrovirus Conference 2016.  (February 2016, Beta Blog)
• PrEP use rising among high-risk gay men in Washington State.  (February 2016, AIDSmap)
• Combination nanotherapy drastically reduces the amount of HIV produced by cells in mice.  (February 2016, AIDSmap)
• Gilead Seeks Approval of Truvada as PrEP in Europe.  (February 2016, Poz)
• London sexual health clinics step up their support for people buying PrEP online.  (January 2016, AIDSmap)
• We Aren’t the Sex Police: What PrEP Providers Say About Condoms & STIs.  (January 2016, Beta Blog)
• ‘Start-up syndrome’ affects some Truvada users for short period.  (January 2016, Healio)
• New PrEP studies will be a challenge, statisticians warn.  (January 2016, AIDSmap)
• PrEP Educational Resources for Transgender People Launch January 22.  (January 2016, Project Inform)
• Tenofovir Alone as PrEP May Fail.  (January 2016, Poz)
• UK strategy could prevent 7,400 MSM HIV infections by 2020.  (January 2016, Healio)
• PrEP, plus increased testing and treatment, could prevent nearly half of HIV infections in gay men in the UK by 2020.  (January 2016, AIDSmap)
• PrEP Could Halve HIV Rate in British Gay Men.  (January 2016, Poz)
• Two cases of PrEP failure on solo tenofovir pose significant research questions.  (January 2016, AIDSmap)
• Short- or Medium-Term PrEP Is Safer Than Aspirin.  (January 2016, Poz)
• Annual testing and scale-up of PrEP could slow the Dutch gay HIV epidemic.  (January 2016, AIDSmap)
• ViiV and Janssen Secure Plans to Develop Long-Acting HIV Treatment.  (January 2016, Poz)
• Lessons learnt from the history of contraception are relevant for the implementation of PrEP.  (January 2016, AIDSmap)
• Modeling does the math to add up impacts of HIV answers in the works.  (January 2016, Science Speaks Blog)
• Sexy PrEP Ads Appeal to Pleasure.  (December 2015, Beta Blog)
• Is it important for PrEP programs to talk about sex and pleasure, not just prevention?  (December 2015, Beta Blog)
• PrEP Protects Breastfeeding Infants from HIV for Up to a Year.  (December 2015, Poz)
• Drug Resistance from Truvada as PrEP Does Not Last.  (December 2015, Poz)
• Evidence for PrEP efficacy grows, but implementation presents challenges.  (December 2015, AIDSmap)
• No New HIV Infections in San Francisco Community PrEP Clinic.  (December 2015, Beta Blog)
• Discussion of HIV prevention strategies generates ‘enthusiasm and excitement.’  Video dated December 2015, Healio)
• Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued.  (December 2015, AIDSmap)
• Ipergay PrEP study results published.  (December 2015, AIDSmap)
• Many more people could benefit from HIV PrEP but not enough doctors are aware, says CDC.  (December 2015, AIDSmap)
• Non-Daily PrEP Study Raises Doubts of Its Real-World Applicability.  (December 2015, Poz)
• CDC Says 1.2 Million Americans Are Likely Candidates for PrEP.  (November 2015, Poz)
• France approves PrEP.  (November 2015, AIDSmap)
• Mon Dieu, France Approves PrEP!  (November 2015, Poz)
• Barcelona clinic study counts how many gay men might benefit from PrEP.  (November 2015, AIDSmap)
• Very Low HIV Rate in Study of High-Risk Gays on PrEP.  (November 2015, Poz)
• PrEP Works if You Take It for Trans Women Too.  (November 2015, Poz)
• Truvada PrEP appears to work for transgender women, but only if used consistently.  (November 2015, AIDSmap)
• First Studies Spur Confidence in New Ways to PrEP.  (October 2015, Beta Blog)
• Does Truvada as PrEP Stunt Bone Growth in Young Men?  (October 2015, Poz)
• When will Europe get PrEP?  (October 2015, AIDSmap)
• New guidelines demonstrate ‘point of clarity’ in managing HIV transmission with PrEP. (October 2015, Healio)
• More Infectious Disease Docs Are Prescribing PrEP.  (October 2015, Poz)
• Latinos Deserve Access to PrEP, Too.  (October 2015, Beta Blog)
• At least 25,000 people in the US may now be using PrEP.  (October 2015, AIDSmap)
• Gay Men’s Sexual Patterns Predict PrEP Dosing Preferences.  (October 2015, Poz)
• The Role of PrEP for Transgender Women in Peru.  (October 2015, TheBodyPro)
• PrEP preferences in gay men are predicted by the frequency and predictability of the sex they have.  (October 2015, AIDSmap)
• WHO guidelines recommend universal antiretroviral treatment, PrEP for those at substantial risk.  (September 2015, AIDSmap)
• WHO Calls For HIV Treatment For All, Supports Broader PrEP Use.  (September 2015, Poz)
• CDC Supports New WHO Early Release HIV Treatment and PrEP Guidelines.  (September 2015, CDC)
• Treat All People Living With HIV, Offer Antiretrovirals as PrEP for People at Substantial Risk.  (September 2015, WHO)
• WHO ART guideline: Treat all with HIV, offer PrEP to those at “substantial risk.”  (September 2015, Science Speaks Blog)
• Rejecting Good Science on PrEP: Why Does it Happen?  (September 2015, Beta Blog)
• Bone Density Drops About 1% in HIV-Negative MSM and Transgender Women on PrEP.  (September 2015, TheBodyPro)
• Second UK cost-effectiveness study finds that large PrEP programmes may need drug price cut to be affordable.  (September 2015, AIDSmap)
• Preventing HIV With Limited Funds? Choose Treatment Over PrEP.  (September 2015, Poz)
• Is PrEP 100% Effective or 100% Over-Hyped?  (September 2015, TheBodyPro)
• The Overlooked Secondary Benefits of PrEP.  (September 2015, TheBodyPro)
• PROUD PrEP study results published.  (September 2015, AIDSmap)
• PROUD Study Results Strongly Support UK PrEP Use in New Paper.  (September 2015, Poz)
• U.S. PrEP care cascade analysis suggests that major, structural barriers need to be addressed for PrEP to have an impact.  (September 2015, AIDSmap)
• Gays Are Talking About PrEP and Viral Load on Social Apps.  (September 2015, Poz)
• Half of American gay men using dating apps have interacted with a PrEP user.  (September 2015, AIDSmap)
• No HIV infections seen in San Francisco PrEP users referred via primary care.  (September 2015, AIDSmap)
• After 2.5 Years, No One in Large SF PrEP Group Contracts HIV.  (September 2015, Poz)
• PrEP ‘Care Continuum’ IDs Barriers to Effective HIV Prevention.  (September 2015, Poz)
• Highest-Risk Gay and Bi Men Likeliest to Join Brazilian PrEP Study.  (August 2015, Poz)
• Where Do I Fit In? PrEP and Transgender Men.  (August 2015, Beta Blog)
• AIDS Healthcare Foundation Cedes Ground in Anti-PrEP Fight.  (August 2015, Poz)
• PrEP Is Safe for People With Hepatitis B.  (August 2015, Poz)
• Daily PrEP lowers hip, spine BMD in HIV-seronegative patients.  (August 2015, Healio)
• People with hepatitis B can safely use Truvada PrEP for HIV prevention.  (August 2015, AIDSmap)
• Study sheds light on how tenofovir is processed in different body tissues.  (August 2015, AIDSmap)
• First Brazilian PrEP data reinforce evidence that PrEP is most used by those at greatest risk.  (August 2015, AIDSmap)
• Open-label PrEP in Botswana: very high adherence and no HIV infections seen.  (August 2015, AIDSmap)
• Flow Chart for Accessing PrEP for HIV Prevention. (August 2015, Project Inform)
• AIDS Conference Bolsters the Use of HIV Meds as Prevention.  (August 2015, Poz)
• PrEP Update: Hopeful Trends but Social Challenges Persist.  (July 2015, TheBodyPro)
• Some PrEP Success Among White and Latino Gay Youth.  (July 2015, Poz)
• PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently.  (July 2015, AIDSmap)
• Daily dosing and text message reminders associated with PrEP adherence in gay men.  (July 2015, Project Inform Blog)
• Gay youth PrEP study finds good retention and reasonable adherence.  (July 2015, AIDSmap)
• Non-Daily PrEP Likely Works For Anal, Not Necessarily Vaginal, Sex.  (July 2015, Poz)
• People with Housing and Higher HIV Risk are More Adherent to PrEP.  (July 2015, Beta Blog)
• ATN 110: PrEP Adherence Challenges of Young Black Gay Men.  (July 2015, Beta Blog)
• Intermittent PrEP may be a robust strategy for anal sex – vaginal much less certain.  (July 2015, AIDSmap)
• The pros and cons of PrEP: trial volunteers recount their experience of the ADAPT study.  (July 2015, AIDSmap)
• Adapting PrEP to Match Sex Patterns.  (July 2015, Beta Blog)
• New PrEP & women studies: High adherence and effectiveness, but caution for providers.  (July 2015, Project Inform Blog)
• Excellent Adherence, No New HIV Cases in Heterosexual PrEP Trial.  (July 2015, Poz)
• Gay and Bi Men Adhere Well to PrEP in U.S. Real-World Study.  (July 2015, Poz)
• Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing.  (July 2015, AIDSmap)
• Study results help guide real-world PrEP implementation.  (July 2015, International AIDS Society)
• Vancouver Consensus Statement calls for early access to treatment and PrEP worldwide.  (July 2015, AIDSmap)
• Black market for Truvada PrEP may undermine treatment adherence in marginalised people living with HIV.  (July 2015, AIDSmap)
• Where next in PrEP and microbicides? Europeans discuss research pipeline.  (July 2015, AIDSmap)
• AIDS Healthcare Foundation Issues Latest Anti-PrEP Salvo.  (June 2015, Poz)
• Provision of PrEP in the UK will be cost-effective for gay men at high risk of HIV, model finds.  (June 2015, AIDSmap)
• PrEP Reaches Top Effectiveness After a Week of Daily Dosing.  (May 2015, Poz)
• Prioritisation is crucial for the success of PrEP, model confirms.  (May 2015, AIDSmap)
• Truvada PrEP causes only mild loss of bone mineral density.  (May 2015, AIDSmap)
• PrEP Prescriptions on Dramatic Upswing in New York State.  (May 2015, Poz)
• PrEP-Delivering Subdermal Implant Shows Promise in Animal Study.  (May 2015, Poz)
• VIDEO: Expert discusses emerging viruses, hepatitis C treatment, HIV prophylaxis.  (May 2015, Healio)
• Injectable PrEP: The Next Order of the Day.  (May 2015, Beta Blog)
• Capping Coinsurance Payments for PrEP and HIV Meds.  (April 2015, Beta Blog)
• Gay and Bi Men Eager to Enter PrEP Demonstration Project.  (April 2015, Poz)
• Truvada as PrEP Leads to Small Initial Decrease in Bone Density.  (April 2015, Poz)
• Women in Failed PrEP Trial Lied About Pill Use to Stay In Study.  (April 2015, Poz)
• Daily PrEP leads to better adherence and protective drug levels in women.  (April 2015, AIDSmap)
• Drug resistance possible risk for PrEP.  (April 2015, Healio)
• Poll of HIV Providers Finds Some Reluctance Toward PrEP Prescribing.  (April 2015, Poz)
• How Should Providers Incorporate PrEP Into Busy Clinical Practices?  (April 2015, TheBodyPro)
• Women in PrEP trial feared they would have to leave study if they reported low adherence.  (April 2015, AIDSmap)
• PrEP and Drug Resistance: Cause for Concern?  (April 2015, Beta Blog)
• No Matter How You Slice It, PrEP Rollout Should Save Money.  (April 2015, Poz)
• How Do We Overcome the Challenges of Accessing PrEP?  (March 2015, TheBodyPro)
• PrEP Is Ready for Primetime.  (March 2015, Poz)
• Canada: PrEP use now could save considerable sums in the future.  (March 2015, AIDSmap)
• Dr. Robert Grant: What Does Ipergay Tell Us About PrEP and ‘Seasons of Risk’?  (March 2015, Beta Blog)
• Single Dose of Selzentry Does Not Reach Levels High Enough for PrEP.  (March 2015, Poz)
• As PrEP Use in San Francisco Rises, Hope for Cutting HIV Rates.  (March 2015, Poz)
• PrEP as bridge to ART highly successful in HIV prevention.  (March 2015, Healio)
• Levels of maraviroc in vaginal and rectal tissues may not be high enough for pre-exposure prophylaxis.  (March 2015, AIDSmap)
• Prevention, Treatment Combine to Avert HIV Infection.  (February 2015, MedPage Today)
• Daily PrEP + ARVs in Mixed-HIV Status Couples = Prevention Success.  (February 2015, Poz)
• Combining PrEP and ART could almost eliminate HIV infection, east African study finds.  (February 2015, AIDSmap)
• PrEP use high, effective among HIV serodiscordant African couples.  (February 2015, Healio)
• Video: PrEP promising, but requires more exploration.  (February 2015, Healio)
• Sex-based PrEP cuts infections by 86%.  (February 2015, Project Inform)
• Daily PrEP reduces HIV infections by 86% in U.K. PROUD Study.  (February 2015, Project Inform)
• Wider PrEP Use in San Francisco Could Cut New HIV Rate by 70%.  (February 2015, NATAP)
• PrEP use rising in San Francisco, but scaling up could further cut new infections.  (February 2015, AIDSmap)
• Studies Cement Value of HIV Prophylaxis.  (February 2015, MedPage Today)
• “On-Demand” PrEP Shows High Efficacy in IPERGAY Trial.  (February 2015, Beta Blog)
• Partners PrEP Demo project: Near Elimination of HIV Transmission with ART and PrEP.  (February 2015, Beta Blog)
• ‘On-demand’ PrEP regimen successful among MSM.  (February 2015, Healio)
• PrEP demonstrates more protection than expected in real-life setting.  (February 2015, Healio)
• AVAC calls for rapid response to new ARV-based HIV prevention data presented at CROI, including expedited regulatory review, expanded rollout and updated research plans.  (February 2015, AVAC)
• New PrEP Results Exceed HIV Researchers’ High Expectations.  (February 2015, TheBodyPro)
• PROUD Study of “Real World” PrEP Reports 86% Efficacy.  (February 2015, Beta Blog)
• Study shows “Near elimination of HIV transmission” in a demonstration of PrEP as a bridge to treatment.  (February 2015, Science Speaks Blog)
• PrEP, microbicide findings show divergent paths of prevention responses.  (February 2015, Science Speaks Blog)
• Intercourse-Based PrEP Dosing Lowers HIV Risk in Gays, But Why?  (February 2015, Poz)
• Pre-exposure prophylaxis (PrEP) stops 86% of HIV infections in PROUD study.  (February 2015, AIDSmap)
• Pre-exposure prophylaxis also stops 86% of HIV infections in Ipergay study.  (February 2015, AIDSmap)
• PrEP Reduces Group of Gay Men’s Risk of HIV By 86% in UK Study.  (February 2015, Poz)
• PrEP-ing for Prevention at CROI 2015.  (February 2015, Beta Blog)
• Women and PrEP: The Bridging Role of Local Health Departments.  (February 2015, TheBodyPro)
• Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme.  (February 2015, AIDSmap)
• PrEP in the Spotlight: Sound Bites from Creating Change.  (February 2015, Beta Blog)
• PrEP Users Sexually Acquired Hep C Suggests Need for Routine Testing.  (February 2015, Poz)
• 10 HIV Prevention Developments to Watch in 2015.  (February 2015, AVAC and TheBodyPro)
• Failed VOICE PrEP Trial Failed to Preempt Lies About Adherence.  (February 2015, Poz)
• How Well Do Condoms and PrEP Prevent HIV Among Gay and Bi Men?  (February 2015, Poz)
• Primate Studies Raise Hope of Eventual Quarterly Injected PrEP.  (January 2015, Poz)
• While Rare, Drug Resistance After Contracting HIV on PrEP Can Occur.  (January 2015, Poz)
• Gay Men’s Ability to Predict Having Sex Has Implications for PrEP Dosing.  (January 2015, Poz)
• CDC Vastly Expands ‘Prevention With Positives’ Guidelines.  (January 2015, Poz)
• U.S. guidelines on prevention with people living with HIV now emphasise engagement with care, HIV treatment and social factors.  (January 2015, Poz)
• No new HIV infections seen among Kaiser PrEP users.  (December 2014, AIDSmap)
• Zero HIV Infections Among PrEP Users With 45% Reporting Less Condom Usage.  (December 2014, TheBodyPro)
• Pushing PrEP in HIV ‘Hot Zones’ Better Combats the Virus.  (December 2014, Poz)
• 45% of PrEP Users at SF Clinic Report Using Condoms Less Often.  (December 2014, Poz)
• 6 Lessons for Health Departments Using PrEP as an HIV Prevention Tool.  (December 2014, National Alliance of State and Territorial AIDS Directors.
• Conceiving a Child on Truvada as PrEP Appears Safe.  (December 2014, Poz)
• IPERGAY PrEP study shows early efficacy in protecting gay men from HIV: all participants to switch to active drug.  (November-December 2014, HIV Treatment Bulletin)
• UK PROUD study to provide PrEP to all participants earlier than expected: planned follow-up to continue to two years.  (November-December 2014, HIV Treatment Bulletin)
• NHS urgently needs to make PrEP available, say HIV prevention organisations.  (November 2014, AIDSmap)
• Uncertainty About PrEP Persists Among Physicians in the United States.  (November 2014, TheBodyPro)
• What Does 2015 Hold in Store for HIV Research?  (November 2014, TheBodyPro)
• Truvada PrEP use rising in United States, especially among men.  (November 2014, AIDSmap)
• Latest Data on PrEP, Though Patchy, Indicates Rising Use Among Men.  (November 2014, Poz)
• Why Women May Not Be Protected From HIV by Intermittent PrEP Dosing.  (November 2014, TheBodyPro)
• More PrEP Needed To Prevent HIV Via Vaginal Than Anal Sex.  (November 2014, Poz)
• Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex.  (November 2014, AIDSmap)
• Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine.  (October 2014, AIDSmap)
• Why the IPERGAY (Yes, That’s Its Name) Study Could Substantially Increase Use of PrEP.  (October 2014, Journal Watch on TheBodyPro)
• “On Demand” PrEP May Significantly Reduce HIV Risk; IPERGAY Study Halted.  (October 2014, TheBodyPro)
• From Routine to Sexy, More PrEP Options Are a Plus for HIV Prevention.  (October 2014, TheBody)
• High Efficacy Halts Placebo Phase of Intermittent PrEP Study.  (October 2014, Poz)
• Second European PrEP study is closed early due to high effectiveness.  (October 2014, AIDSmap)
• Calculating PrEP’s Capacity to Prevent HIV in the Real World.  (October 2014, Poz)
• High Efficacy for PrEP Among Gay Men in English Study.  (October 2014, Poz)
• Long-Acting, Investigational Integrase Inhibitor Cabotegravir Shows Promise.  (October 2014, TheBody)
• High effectiveness seen in English PrEP trial.  (October 2014, AIDSmap)
• Analysis of PrEP Data Shows High Adherence in U.S., and Among Most at Risk of HIV.  (October 2014, TheBody)
• Washington State First to Assist Those Seeking HIV Prevention Pill.  (October 2014, TheBody)
• PrEP will need high adherence, high effectiveness and high coverage in specific populations to be affordable in the US, New York study finds.  (October 2014, AIDSmap)
• Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP.  (September/October 2014, HIV Treatment Bulletin)